Piper Sandler raised the firm’s price target on Kymera Therapeutics (KYMR) to $125 from $98 and keeps an Overweight rating on the shares. The firm notes Kymera reported impressive Phase Ib BroADen data, initiated the Phase IIb BROADEN2 trial of 3 doses of KT-621 in 200 atopic dermatitis patients and will initiate the Phase IIb BREADTH trial in asthma in Q1 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $110 from $80 at Citi
- Kymera Therapeutics price target raised to $112 from $71 at BofA
- Kymera Therapeutics price target raised to $116 from $69 at Wells Fargo
- Kymera Therapeutics price target raised to $119 from $70 at Barclays
- Kymera Therapeutics’ KT-621: Promising Market Potential and Competitive Positioning in Atopic Dermatitis Treatment